Sign In
Last checked at 
25 Nov 2015 18:06
25 November 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Grant of Options under Long Term Incentive Plan
Allergy Therapeutics plc confirms that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 30 June 2015, details of which were announced on 19 December 2012, have been met. Consequently, Allergy Therapeutics has today granted certain of its directors nil cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP as follows:
Director | Number of Ordinary Shares over which Options granted | Total number of Ordinary Shares over which Options granted | Total remaining number of Ordinary Shares provisionally awarded under LTIPs |
Manuel Llobet, Chief Executive Officer | 624,024 | 624,024 | 2,595,000 |
Ian Postlethwaite, Finance Director | 312,012 | 475,512 | 1,297,500 |
The Options have been granted in accordance with the LTIP rules and can be exercisable at nil cost between 25 December 2015 and 25 December 2018.
For further information:
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
Panmure Gordon | +44 (0) 20 7886 2500 |
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance | |
Tom Salvesen, Corporate Broking | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell |
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £43 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.
Follow the stocks
